NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
Updated: Feb 10
IsKPd - IFM2018-03
NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Isa-KPd
IsKPd - IFM2018-03
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma.
Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment phase After cycle 13 : maintenance phase
Sponsor Poitiers University Hospital
Collaborators
Sanofi
Celgene
Amgen
Intergroupe Francophone du Myelome
ClinicalTrials.gov Identifier: NCT04287855
Official Title: Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
First Posted : February 27, 2020
Click here to see details on ClinicalTrials.gov
Drug: Isatuximab
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Dexamethasone
Location France